Gossamer Bio, Inc.
NASDAQ:GOSSBiotechnology
+$0.01 today
- Market cap
- $67.52M
- Beta
- 2.04
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.77
Volume 0.22M
Average 19.76M
GOSS EBITDA Margin
EBITDA as a percentage of revenue.
Gossamer Bio, Inc.NASDAQ: GOSS
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -257.6%
EBITDA Margin was -257.6% in Q1 FY2026, up 81.7 pp from a year earlier. On a trailing-twelve-month basis it was -304.0%, down 275.3 pp year over year.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 4 analysts of -124.6% for the fiscal year ending Dec 2026, up from -326.9% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -257.6%+63.8 pp QoQ
- Last fiscal yearDec 2025
- -326.9%-292.1 pp YoY
- LTMMar 2026
- -304.0%-275.3 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +81.7 pp | -1388.0 pp | -1469.6 pp |
| 1 year | -292.1 pp | +202.3 pp | +494.4 pp |
| 3 years | — | +326.9 pp | — |
| 5 years | +340.8 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -326.9%
- Year-over-year change
- -292.1pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -326.9% | -292.1pp |
| FY2024 | 2024-12-31 | -34.8% | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | — | — |
EBITDA Margin vs competitors
How GOSS compares with its peers on the latest reported figures
- GOSS's LTM Mar 2026 EBITDA Margin of -304.0% is the lowest of the 7 companies compared; the peer median is -115.0%.
- Its year-over-year change of -275.3 pp is the lowest of 6, against a peer median of +19.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 43.8% | +19.9 pp | +89.5 pp | |
| LTM Mar 2026 | -25.0% | +470.9 pp | +71883.1 pp | |
| LTM Dec 2025 | -101.1% | — | — | |
| LTM Mar 2026 | -129.0% | -45.6 pp | -1804.0 pp | |
| LTM Mar 2026 | -185.2% | +738962.6 pp | +3203.1 pp | |
| LTM Mar 2026 | -261.2% | -183.0 pp | +138.5 pp | |
| LTM Mar 2026 | -304.0% | -275.3 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding GOSS) | -115.0% | +19.9 pp | +138.5 pp | |
Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 114.7M | 48.47M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1M |
| Gross Profit | 0 | 0 | 0 | 114.7M | 47.47M |
| Gross Margin | — | — | — | 100.0% | 97.9% |
| Research & Development | 170.27M | 170.92M | 135.3M | 138.49M | 174.09M |
| Selling, General & Admin | 45.78M | 47.61M | 38.46M | 36.13M | 37.63M |
| Operating Expenses | 216.12M | 218.59M | 183.76M | 174.62M | 210.72M |
| Depreciation & Amortization | 5.17M | 4.43M | 4.39M | 4.15M | 1M |
| EBITDA | (209.4M) | (211.07M) | (161.92M) | (39.97M) | (158.47M) |
| EBITDA Margin | — | — | — | -34.8% | -326.9% |
| Operating Income | (216.12M) | (218.59M) | (183.76M) | (59.92M) | (163.25M) |
| Operating Margin | — | — | — | -52.2% | -336.8% |
| Interest Income | 761K | 1.58M | 2M | 1.78M | 1.97M |
| Interest Expense | 19.44M | 13.88M | 13.51M | 11.52M | 10.99M |
| Other Income / Expenses | (17.88M) | (10.79M) | 3.94M | 4.28M | (7.21M) |
| Income Before Tax | (234M) | (229.38M) | (179.82M) | (55.64M) | (170.46M) |
| Pre-Tax Margin | — | — | — | -48.5% | -351.7% |
| Income Tax Expense | 0 | 0 | 0 | 893K | (88K) |
| Net Income | (234M) | (229.38M) | (179.82M) | (56.53M) | (170.37M) |
| Net Margin | — | — | — | -49.3% | -351.5% |
| EPS (Basic) | (3.33) | (2.84) | (0.80) | (0.25) | (0.75) |
| EPS (Diluted) | (3.33) | (2.84) | (1.18) | (0.25) | (0.75) |
| Weighted Avg Shares | 74.84M | 84.57M | 225.57M | 226.23M | 228.52M |
| Weighted Avg Shares (Diluted) | 74.84M | 84.57M | 225.57M | 226.23M | 228.52M |
Gossamer Bio, Inc.
NASDAQ:GOSS
Intrinsic Alpha fair value
Locked
Current Price
$11.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.